High-Level Expression of the Smad Ubiquitin Ligase Smurf 2 Correlates with Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma 1

Transforming growth factor (TGF) regulates growth of various cells, and inactivation of the TGFsignaling pathway contributes to tumor progression. Smad2 is phosphorylated and activated by TGF, resulting in the antiproliferative effects of TGFsignaling. Smurf2 (Smad ubiquitination regulatory factor 2) was identified as the Smad ubiquitin ligase that induces the ubiquitination and degradation of Smad2. This study was undertaken to elucidate the relationships between Smurf2 expression and the clinicopathological characteristics of patients with esophageal squamous cell carcinoma (SCC) and the correlation between Smurf2 and Smad2 expression. Surgical specimens obtained from 80 patients with esophageal SCC were subjected to immunohistochemical staining. Our data indicated that high-level expression of Smurf2 correlated with depth of invasion, lymph node metastasis, and a poor survival rate. We also found an inverse correlation between the expression of Smurf2 and Smad2. Western blotting analysis of esophageal SCC-derived cell lines revealed similar inverse correlations. We demonstrated that high-level expression of Smurf2 appears to correlate with tumor development and poor prognosis in patients with esophageal SCC and that alteration of Smad2 expression in the TGFsignaling pathway may be induced by enhancement of Smad2 degradation mediated by high-level expression of Smurf2.

[1]  H. Kuwano,et al.  Decreased Smad4 expression in the transforming growth factor‐β signaling pathway during progression of esophageal squamous cell carcinoma , 2002, Cancer.

[2]  C. Muro-Cacho,et al.  Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  A. Atfi,et al.  Mechanism for Mutational Inactivation of the Tumor Suppressor Smad2 , 2001, Molecular and Cellular Biology.

[4]  R. Derynck,et al.  Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Wrana,et al.  Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. , 2000, Molecular cell.

[6]  Xia Lin,et al.  Smurf2 Is a Ubiquitin E3 Ligase Mediating Proteasome-dependent Degradation of Smad2 in Transforming Growth Factor-β Signaling* 210 , 2000, The Journal of Biological Chemistry.

[7]  R. Derynck,et al.  Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15Ink4B transcription in response to TGF‐β , 2000 .

[8]  H. Kuwano,et al.  Mutation analysis of transforming growth factor beta type II receptor, Smad2, Smad3 and Smad4 in esophageal squamous cell carcinoma. , 2000, International journal of oncology.

[9]  A. Ciechanover,et al.  The ubiquitin system , 2000, Nature Medicine.

[10]  J. Massagué,et al.  Ubiquitin-dependent degradation of TGF-β-activated Smad2 , 1999, Nature Cell Biology.

[11]  Jeffrey L. Wrana,et al.  A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation , 1999, Nature.

[12]  M. Hochstrasser,et al.  Substrate Targeting in the Ubiquitin System , 1999, Cell.

[13]  H. Saeki,et al.  Proliferative activity of cancer cells in front and center areas of carcinoma in situ and invasive sites of esophageal squamous‐cell carcinoma , 1998, International journal of cancer.

[14]  R. White,et al.  Tumor Suppressing Pathways , 1998, Cell.

[15]  Kohei Miyazono,et al.  TGF-β signalling from cell membrane to nucleus through SMAD proteins , 1997, Nature.

[16]  K. Kinzler,et al.  Frequency of Smad gene mutations in human cancers. , 1997, Cancer research.

[17]  Kohei Miyazono,et al.  Positive and negative regulation of TGF-β signaling , 2000 .

[18]  J. Massagué,et al.  TGF- SIGNAL TRANSDUCTION , 1998 .

[19]  S. Markowitz,et al.  Tumor suppressor activity of the TGF-beta pathway in human cancers. , 1996, Cytokine & growth factor reviews.